For those seeking core competencies and updates in heart failure care, this specific bundle continuing pharmacy credits (CPE) from key sessions from the HFSA Annual Scientific Meeting 2021.

With the 2021 HFSA ASM Pharmacy Bundle, learners can:

• Claim up to 24.75 contact hours of knowledge-based CPE
• Watch 20 highly rated and attended sessions from the HFSA Annual Scientific Meeting 2021. Including the highly attended:
  • Late Breaking Clinical Trials I
  • Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i
  • Debate: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy
  • Beyond PVR:  Assessing and Managing the Dysfunctional Right Ventricle (audio is poor -- sometimes low and sometimes high)
  • Recent Advances and Update on Myocarditis

2021 Program Committee Co-Chairs

Larry Allen, MD, MHS, FHFSA
Katherine E. Di Palo, PharmD, BCACP, BCGP, FHFSA
Walter J. Koch, PhD
Marianne R. Piano, PhD, RN

Program Committee

Amrut Ambardekar, MD

Alpesh Amin, MD, MBA

Mosi Bennett, MD, PhD

Rob DiDomenico, PharmD

Akshay Desai, MD, MPH

Teri Diederich, NP

Timothy Fendler, MD

Megan Fraser, DNP, ANP-C

Daniel Garry, MD, PhD

Ashley Hardin, MD

Line Kemeyou, MD

David Lanfear, MD, MS

Alanna Morris, MD, MSc

Ajith Nair, MD

Melissa Owen, RN, PhD

Jo Ellen Rodgers, PharmD

Amil Shah, MD, MPH

Jeffrey Teuteberg, MD

Emily Tsai, MD

Cheryl Westlake, PhD, RN

Sandip Zalawadiya, MD

• Cardiac Amyloidosis
• Sarcoidosis
• Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i
• Beyond PVR:  Assessing and Managing the Dysfunctional Right Ventricle (audio is poor -- sometimes low and sometimes high)
• Debate: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy
• Unintended Side Effects: Polypharmacy, Adherence, & Financial Toxicity of Evolving GDMT for Heart Failure
• Recent Advances and Update on Myocarditis
• Substance use in Tx and LVAD Candidates
• COVID and the HF Clinician
• Burned Out: Identifying and Managing Clinician Burnout and Mental Wellness
• Role of Diet, Nutrition, & Body Composition in Patients with HF
• Pulmonary Arterial Hypertension: Providing Comprehensive Care Based on Risk
• Virtual Health
• Emerging Devices/Procedures for Heart Failure
• Care Transitions: Methods, Medications, Metrics, and More!
• Cardio-oncology
• Late Breaking Clinical Trials I
• International Session - Universal Definition of HF
• Optimizing LVAD Management
• Failing Organs in Patients with Advanced HF, Will a Cardiac Fix Fix the Rest?

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event is accredited for up to 24.75 contact hours of knowledge-based CPE.

ACPE Universal Activity Number (UAN): JA4008267-0000-22-006-H04-P